Full Press Release Details
Aclaris Announces Proposed Public Offering
WAYNE, Pa., January 19, 2021 (GLOBE NEWSWIRE) --
Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates
for immuno-inflammatory diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its
common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered
by Aclaris. Aclaris also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of
its common stock offered in the public offering on the same terms and conditions. The offering is subject to market conditions,
and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Cantor Fitzgerald & Co. and William Blair & Company,
L.L.C. are acting as joint book-running managers for the offering. H.C. Wainwright & Co., LLC is acting as lead manager for
A shelf registration statement relating to the shares of common
stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on March
13, 2020 and declared effective by the SEC on April 29, 2020. The offering will be made only by means of a written prospectus
and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying
prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Cantor
Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022; Email: prospectus@cantor.com;
or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone
at (800) 621-0687 or by email at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or
the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in
any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring
protein kinase regulation.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Aclaris Therapeutics, Inc., including statements about Aclaris' anticipated public offering
and other statements containing the words "anticipate," "believe," "estimate," "expect,"
"intend," "may," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue,"
and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act
of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important
factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated
terms or at all and such other factors as are set forth in the risk factors detailed in Aclaris' Annual Report on Form 10-K
for the year ended December 31, 2019, Aclaris' Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and
other filings Aclaris makes with the SEC from time to time. In addition, the forward-looking statements included in this
press release represent Aclaris' views as of the date hereof. Aclaris anticipates that subsequent events and developments
will cause Aclaris' views to change. However, while Aclaris may elect to update these forward-looking statements at some
point in the future, Aclaris specifically disclaims any obligation to do so. These forward-looking statements should not be relied
upon as representing Aclaris' views as of any date subsequent to the date hereof.